- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Unrestricted benefit
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 334KB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 50KB)
Medroxyprogesterone acetate – November 2023
Medroxyprogesterone acetate: Suspension for injection 150 mg in 1 mL pre-filled syringe; Depo-Provera®
Last updated
1 March 2024